Several inactivating TGFBR2 mutations have been reported in various cancers, including truncation mutations in microsatellite‐instable patients as well as missense mutations in the kinase domain.35 One study reported a TGFBR2 mutation that enhanced TGF‐β signaling.36 Here, we report two new TGFBR2 missense mutations that inhibit SMAD‐dependent TGF‐β signaling (Figure 4). This evidence concerns the gene TGFB1 and cancer.